Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

NCT07708714 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
250
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators